Zydus starts phase II trials of molecule targeting anaemia

Anaemia commonly arises in kidney disease patients, because the kidneys no longer produce sufficient amounts of erythropoietin, a hormone which stimulates red blood cell production.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news